MX2023002650A - Metodos de tratamiento del dolor por cancer mediante la administracion de un inhibidor de pd-1. - Google Patents
Metodos de tratamiento del dolor por cancer mediante la administracion de un inhibidor de pd-1.Info
- Publication number
- MX2023002650A MX2023002650A MX2023002650A MX2023002650A MX2023002650A MX 2023002650 A MX2023002650 A MX 2023002650A MX 2023002650 A MX2023002650 A MX 2023002650A MX 2023002650 A MX2023002650 A MX 2023002650A MX 2023002650 A MX2023002650 A MX 2023002650A
- Authority
- MX
- Mexico
- Prior art keywords
- patient
- inhibitor
- administering
- methods
- cancer
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 239000012270 PD-1 inhibitor Substances 0.000 title abstract 3
- 239000012668 PD-1-inhibitor Substances 0.000 title abstract 3
- 229940121655 pd-1 inhibitor Drugs 0.000 title abstract 3
- 206010058019 Cancer Pain Diseases 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 3
- 230000000202 analgesic effect Effects 0.000 abstract 3
- 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 238000002560 therapeutic procedure Methods 0.000 abstract 2
- 208000002193 Pain Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente descripción provee métodos para tratar o inhibir el dolor por cáncer en un paciente que lo necesite, incluida la selección de un paciente con cáncer y la administración al paciente de una cantidad terapéuticamente eficaz de un inhibidor de muerte programada 1 (PD-1). La presente descripción también provee métodos para reducir el uso de analgésicos en un paciente que lo necesite, incluida la selección de un paciente con cáncer y la administración al paciente de una cantidad terapéuticamente eficaz de un inhibidor de PD-1, en donde el paciente está siendo tratado con una terapia con analgésicos de base antes de la administración del inhibidor de PD-1. En algunas modalidades, los métodos descritos conducen al mismo tiempo a la regresión del tumor, la reducción del dolor y la reducción del uso de la terapia con analgésicos.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063074282P | 2020-09-03 | 2020-09-03 | |
US202163161519P | 2021-03-16 | 2021-03-16 | |
US202163186375P | 2021-05-10 | 2021-05-10 | |
EP21315132 | 2021-07-29 | ||
PCT/US2021/048785 WO2022051448A1 (en) | 2020-09-03 | 2021-09-02 | Methods of treating cancer pain by administering a pd-1 inhibitor |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2023002650A true MX2023002650A (es) | 2023-06-08 |
Family
ID=77924529
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2023002650A MX2023002650A (es) | 2020-09-03 | 2021-09-02 | Metodos de tratamiento del dolor por cancer mediante la administracion de un inhibidor de pd-1. |
Country Status (10)
Country | Link |
---|---|
US (1) | US11932692B2 (es) |
EP (1) | EP4208258A1 (es) |
JP (1) | JP2023542490A (es) |
KR (1) | KR20230061499A (es) |
CN (1) | CN116194142A (es) |
AU (1) | AU2021337650A1 (es) |
CA (1) | CA3170207A1 (es) |
IL (1) | IL300975A (es) |
MX (1) | MX2023002650A (es) |
WO (1) | WO2022051448A1 (es) |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001014557A1 (en) | 1999-08-23 | 2001-03-01 | Dana-Farber Cancer Institute, Inc. | Pd-1, a receptor for b7-4, and uses therefor |
PT2206517T (pt) | 2002-07-03 | 2023-11-07 | Tasuku Honjo | Composições de imunopotenciação contendo anticorpos anti-pd-l1 |
ES2367430T3 (es) | 2002-12-23 | 2011-11-03 | Wyeth Llc | Anticuerpos contra pd-1 y sus usos. |
EP1591527B1 (en) | 2003-01-23 | 2015-08-26 | Ono Pharmaceutical Co., Ltd. | Substance specific to human pd-1 |
US8257740B1 (en) | 2011-08-15 | 2012-09-04 | Gp Medical, Inc. | Pharmaceutical composition of nanoparticles |
ES2427646T5 (es) | 2005-05-09 | 2017-08-22 | Ono Pharmaceutical Co., Ltd. | Anticuerpos monoclonales humanos contra muerte programada 1 (PD1) y métodos para el tratamiento del cáncer mediante el uso de anticuerpos anti-PD-1 solos o combinados con otros agentes inmunoterapéuticos |
US8246995B2 (en) | 2005-05-10 | 2012-08-21 | The Board Of Trustees Of The Leland Stanford Junior University | Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells |
MX2007015942A (es) | 2005-07-01 | 2008-03-07 | Medarex Inc | Anticuerpos monoclonales humanos para ligandos 1 (pd-l1) de muerte programada. |
RS53072B (en) | 2007-06-18 | 2014-04-30 | Merck Sharp & Dohme B.V. | HUMAN RECEPTOR ANTIBODIES PROGRAMMED DEATH PD-1 |
CA2698419C (en) | 2007-09-07 | 2019-11-12 | Edward Dolk | Binding molecules with multiple binding sites, compositions comprising the same and uses thereof |
EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
WO2010027423A2 (en) | 2008-08-25 | 2010-03-11 | Amplimmune, Inc. | Compositions of pd-1 antagonists and methods of use |
PL2342226T3 (pl) | 2008-09-26 | 2017-01-31 | Dana-Farber Cancer Institute, Inc. | Ludzkie przeciwciała anty-PD-1, PD-L1 i PD-L2 oraz ich zastosowania |
HUE034832T2 (hu) | 2008-12-09 | 2021-12-28 | Hoffmann La Roche | Anti-PD-L1 antitestek és alkalmazásuk T-sejt-funkció fokozására |
TW201134488A (en) | 2010-03-11 | 2011-10-16 | Ucb Pharma Sa | PD-1 antibodies |
US9163087B2 (en) | 2010-06-18 | 2015-10-20 | The Brigham And Women's Hospital, Inc. | Bi-specific antibodies against TIM-3 and PD-1 for immunotherapy in chronic immune conditions |
US8686119B2 (en) | 2011-07-24 | 2014-04-01 | Curetech Ltd. | Variants of humanized immunomodulatory monoclonal antibodies |
JP6138813B2 (ja) | 2011-11-28 | 2017-05-31 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung | 抗pd−l1抗体及びその使用 |
KR102228296B1 (ko) | 2012-03-16 | 2021-03-17 | 리제너론 파마슈티칼스 인코포레이티드 | 히스티딘 공학처리된 경쇄 항체 및 그것을 생성하기 위한 유전자 변형된 비-사람 동물 |
RU2689760C2 (ru) | 2012-05-31 | 2019-05-30 | Дженентек, Инк. | Способы лечения рака с применением антагонистов аксиального связывания pd-1 и vegf антагонистов |
KR20220084444A (ko) | 2012-05-31 | 2022-06-21 | 소렌토 쎄라퓨틱스, 인코포레이티드 | Pd-l1에 결합하는 항원 결합 단백질 |
US9308236B2 (en) | 2013-03-15 | 2016-04-12 | Bristol-Myers Squibb Company | Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions |
TWI680138B (zh) | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗pd-l1之人類抗體 |
TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對pd-1的人類抗體 |
CN110964108B (zh) | 2014-08-05 | 2023-07-07 | 中美冠科生物技术(太仓)有限公司 | 抗pd-l1抗体 |
AU2016233495B2 (en) | 2015-03-13 | 2022-02-24 | Cytomx Therapeutics, Inc | Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of use thereof |
KR20180040138A (ko) | 2015-07-13 | 2018-04-19 | 싸이톰스 테라퓨틱스, 인크. | 항pd-1 항체, 활성화 가능한 항pd-1 항체, 및 이들의 사용 방법 |
AR105654A1 (es) | 2015-08-24 | 2017-10-25 | Lilly Co Eli | Anticuerpos pd-l1 (ligando 1 de muerte celular programada) |
JP2019510832A (ja) | 2016-04-07 | 2019-04-18 | ケモセントリクス,インコーポレーテッド | Pd−1阻害剤又はpd−l1阻害剤と組み合わせてccr1アンタゴニストを投与することによる腫瘍負荷の低減 |
TW202408578A (zh) * | 2016-05-13 | 2024-03-01 | 美商再生元醫藥公司 | 藉由投予pd-1抑制劑治療皮膚癌之方法 |
US11603407B2 (en) | 2017-04-06 | 2023-03-14 | Regeneron Pharmaceuticals, Inc. | Stable antibody formulation |
WO2018209329A1 (en) * | 2017-05-12 | 2018-11-15 | Duke University | Methods and kits for treating pain |
US20210147547A1 (en) | 2018-04-13 | 2021-05-20 | Novartis Ag | Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof |
SG11202107396RA (en) | 2019-01-21 | 2021-08-30 | Sanofi Sa | Therapeutic rna and anti-pd1 antibodies for advanced stage solid tumor cancers |
-
2021
- 2021-09-02 AU AU2021337650A patent/AU2021337650A1/en active Pending
- 2021-09-02 JP JP2023514719A patent/JP2023542490A/ja active Pending
- 2021-09-02 CN CN202180054362.7A patent/CN116194142A/zh active Pending
- 2021-09-02 EP EP21778317.4A patent/EP4208258A1/en active Pending
- 2021-09-02 MX MX2023002650A patent/MX2023002650A/es unknown
- 2021-09-02 CA CA3170207A patent/CA3170207A1/en active Pending
- 2021-09-02 IL IL300975A patent/IL300975A/en unknown
- 2021-09-02 KR KR1020237011352A patent/KR20230061499A/ko unknown
- 2021-09-02 WO PCT/US2021/048785 patent/WO2022051448A1/en active Application Filing
- 2021-09-02 US US17/464,819 patent/US11932692B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
AU2021337650A9 (en) | 2024-06-13 |
KR20230061499A (ko) | 2023-05-08 |
CN116194142A (zh) | 2023-05-30 |
CA3170207A1 (en) | 2022-03-10 |
IL300975A (en) | 2023-04-01 |
WO2022051448A1 (en) | 2022-03-10 |
US20220064304A1 (en) | 2022-03-03 |
US11932692B2 (en) | 2024-03-19 |
AU2021337650A1 (en) | 2023-05-04 |
EP4208258A1 (en) | 2023-07-12 |
JP2023542490A (ja) | 2023-10-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP4327882A3 (en) | Enpp1 inhibitors and their use for the treatment of cancer | |
MX2023002248A (es) | Uso de inhibidores de sos1 para tratar neoplasias malignas con mutaciones de shp2. | |
MX2021009269A (es) | Inhibidores de enpp1 y metodos para modular una respuesta inmunitaria. | |
MX2021005651A (es) | Combinacion farmaceutica para el tratamiento contra el cancer. | |
ZA202109010B (en) | Compounds and methods for the treatment of covid-19 | |
MX2022012992A (es) | Inhibidores de kif18a para el tratamiento de enfermedades neoplasicas. | |
WO2009129509A3 (en) | Methods and compositions for treating post-operative pain comprising a local anesthetic | |
HK1078771A1 (en) | Use of the quinazoline derivative zd6474 combined with gemcitabine and optionally ionising radiationin the treatment of cancer | |
MX2023002024A (es) | Métodos de tratamiento con modulador de miosina. | |
MX2023014028A (es) | Inhibidores de cinasa de punto de control 1 (chk1) y usos de los mismos. | |
MX2022009091A (es) | Anticuerpos para usarse en terapia. | |
MX2023010657A (es) | Inhibidores de los retrotransposones largos intercalados del elemento 1 (line-1) para tratar enfermedades del sistema nervioso central (snc) y sistemicas. | |
BR112022010806A2 (pt) | Métodos para tratar câncer de mama, para inibir o crescimento tumoral e para prevenir ou retardar o desenvolvimento de resistência de um câncer de mama | |
BRPI0508982A (pt) | uso de azd2171 ou de um sal deste farmaceuticamente aceitável excluindo um sal de maleato de azd2171, composição farmacêutica, kit, método para o tratamento de um cáncer em um animal de sangue quente tal como um ser humano, e, uso de sal de maleato de azd2171 e 5 - fu e cpt - 11 | |
MX2021007565A (es) | Composiciones y metodos para la terapia contra el cancer. | |
MX2023003332A (es) | Inhibidores del elemento 1 interdispersado largo (line-1) para el tratamiento de enfermedades. | |
MX2023002650A (es) | Metodos de tratamiento del dolor por cancer mediante la administracion de un inhibidor de pd-1. | |
TW200724158A (en) | Combination therapy in the treatment of cancer | |
MX2022001450A (es) | Metodo de tratamiento del cancer. | |
EA202290027A1 (ru) | Способы и композиции для улучшения результатов лечения пациентов с раком | |
MX2020007817A (es) | Prevención y tratamiento del trastorno del sueño. | |
MX2023009279A (es) | Metodos de tratamiento de cancer mediante la administracion de un inhibidor de pd-1 como neoadyuvante. | |
WO2022271810A3 (en) | Bicyclic peptidyl pan-ras inhibitors | |
BRPI0412408A (pt) | métodos para a produção de um efeito de redução antiangiogênico e/ou de permeabilidade vascular e para o tratamento de um cáncer em um animal de sangue quente tal como um ser humano, composição farmacêutica, kit, e uso de azd2171 ou um sal farmaceuticamente aceitável deste e zd1839 ou um sal farmaceuticamente aceitável deste | |
MX2022011725A (es) | Metodos para tratar una lesion pulmonar con inhibidores de cgrp. |